INMED PHARMACEUTICALS INC. Cash and Restricted Cash
INMED PHARMACEUTICALS INC. (INM) had Cash and Restricted Cash of $2.19 million as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-09
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.16M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.95M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.33M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $2.19M S-4/A · filed 2026-09-09 | |
| 2026-03-31 | $5.16M S-4 · filed 2026-07-02 | |
| 2025-12-31 | $6.95M 10-Q · filed 2026-02-11 | |
| 2025-09-30 | $9.33M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $10.74M S-4/A · filed 2026-09-09 | $11.08M 10-K · filed 2025-09-23 |
| 2025-03-31 | $4.68M S-4 · filed 2026-07-02 | |
| 2024-12-31 | $3.42M 10-Q · filed 2026-02-11 | |
| 2024-09-30 | $5.58M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $6.57M S-4/A · filed 2026-09-09 | |
| 2024-03-31 | $7.60M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $9.53M 10-Q · filed 2025-02-12 | |
| 2023-09-30 | $6.74M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $8.91M S-4 · filed 2026-07-02 | |
| 2023-03-31 | $9.60M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $11.45M 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $9.35M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $6.18M 10-K · filed 2024-09-30 | |
| 2022-03-31 | $5.90M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $11.28M 10-Q · filed 2023-02-17 | |
| 2021-09-30 | $15.34M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $7.36M 10-K · filed 2023-09-29 | |
| 2021-03-31 | $9.45M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $10.02M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $4.50M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.81M 10-K · filed 2021-09-24 | |
| 2020-03-31 | $6.97M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $9.20M 10-Q · filed 2021-02-11 | |
| 2019-09-30 | $11.01M 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |